Table 1 Characteristics and miR-128 expression in breast cancer patients
From: MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells
Factors | Patients Number (%) | log (fold repression of miR−128)2 (mean ± SEM) | P value |
|---|---|---|---|
Age(year) | Â | Â | 0.137a |
  ≤ 50 | 13 (39.39%) | − 2.74 ± 1.20 |  |
  > 50 | 20 (60.61%) | − 5.53 ± 1.24 |  |
Tumor size(cm) | Â | Â | 0.279a |
  ≤ 3 | 20 (60.61%) | − 3.63 ± 1.02 |  |
  > 3 | 13 (39.39%) | − 5.68 ± 1.70 |  |
Grade | Â | Â | 0.025a |
 II | 14 (42.42%) | − 2.09 ± 0.79 |  |
 III | 19 (57.58%) | − 6.16 ± 1.36 |  |
TNM stage | Â | Â | 0.639b |
 Ι | 4 (12.12%) | − 2.57 ± 1.49 |  |
 ΙΙ | 22 (66.67%) | − 5.02 ± 1.23 |  |
 ΙΙΙ | 7 (21.21%) | − 3.66 ± 1.72 |  |
ER status | Â | Â | 0.711b |
 Strongly positive | 13 (39.39%) | − 5.23 ± 1.64 |  |
 Mildly positive | 8 (24.24%) | − 3.24 ± 1.45 |  |
 Negative | 12 (36.37) | − 4.37 ± 1.55 |  |
PR status | Â | Â | 0.879b |
 Strongly positive | 6 (18.18%) | − 4.62 ± 2.89 |  |
 Mildly positive | 11 (33.33%) | − 5.02 ± 1.47 |  |
 Negative | 16 (48.49%) | − 3.96 ± 1.26 |  |
HER2 status | Â | Â | 0.817b |
 Strongly positive | 9 (27.27%) | − 4.17 ± 2.21 |  |
 Mildly positive | 20 (60.61%) | − 4.25 ± 1.08 |  |
 Negative | 4 (12.12%) | − 5.97 ± 2.36 |  |
MIB | Â | Â | 0.805a |
  ≤ 20% | 15 (45.45%) | − 4.18 ± 1.39 |  |
  > 20% | 18 (54.55%) | − 4.65 ± 1.24 |  |
Node status | Â | Â | 0.821a |
 Positive | 15 (45.45%) | − 4.20 ± 1.31 |  |
 Negative | 18 (54.55%) | − 4.63 ± 1.30 |  |